Related references
Note: Only part of the references are listed.Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box
Raj Vuppalanchi et al.
HEPATOLOGY (2021)
Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1
Yutao Wang et al.
HEPATOLOGY (2020)
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis
Eduardo Vilar-Gomez et al.
HEPATOLOGY (2020)
High rates of ineligibility for participation in trials of new therapies in non-alcoholic steatohepatitis: a systematic review
Anna Roskilly et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review
Rohit Loomba et al.
GASTROENTEROLOGY (2020)
Redefining non-alcoholic fatty liver disease: what's in a name?
[Anonymous]
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Advances in non-invasive assessment of hepatic fibrosis
Rohit Loomba et al.
GUT (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Jean-Francois Dufour et al.
GUT (2020)
Imaging biomarkers of NAFLD, NASH, and fibrosis
Veeral Ajmera et al.
MOLECULAR METABOLISM (2020)
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Zobair Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants
Cynthia Hsu et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Zobair Younossi et al.
HEPATOLOGY (2019)
MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)
Veeral H. Ajmera et al.
HEPATOLOGY (2019)
Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis
Feng Zhou et al.
HEPATOLOGY (2019)
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis
Jie Li et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH
Rohit Loomba et al.
HEPATOLOGY (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Laurent Castera et al.
GASTROENTEROLOGY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
David E. Kleiner et al.
JAMA NETWORK OPEN (2019)
Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis
Vincent Wai-Sun Wong et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
Rohit Loomba et al.
HEPATOLOGY (2018)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis
Peng Zhang et al.
NATURE MEDICINE (2018)
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2018)
Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials
Cyrielle Caussy et al.
HEPATOLOGY (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases
Jonathan G. Stine et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
Vincent Wai-Sun Wong et al.
JOURNAL OF HEPATOLOGY (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
GASTROENTEROLOGY (2018)
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
Alison D. Marshall et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
Leon A. Adams et al.
GUT (2017)
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial
Melanie Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
Hannes Hagstrom et al.
JOURNAL OF HEPATOLOGY (2017)
Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients
S. Sookoian et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
Sahil Mittal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Pathogenesis and novel treatment options for non-alcoholic steatohepatitis
Vincent Wai-Sun Wong et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis
Ahilan Arulanandan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
Rohit Loomba et al.
HEPATOLOGY (2015)
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
Stuart McPherson et al.
JOURNAL OF HEPATOLOGY (2015)
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial
Vincent Wai-Sun Wong et al.
JOURNAL OF HEPATOLOGY (2013)
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
Kohichiroh Yasui et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
The Natural History of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis or Cirrhosis: An International Collaborative Study
Neeraj Bhala et al.
HEPATOLOGY (2011)
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years
Vincent Wai-Sun Wong et al.
GUT (2010)
The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis
Mustafa S. Ascha et al.
HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver
Nila Rafiq et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
Share Paper
